USA flag logo/image

An Official Website of the United States Government

GENOMICS SCREENING FOR ANTIANGIOGENESIS DRUGS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
59947
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
CA097900
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ONCOTECH, INC.
ONCOTECH, INC. 1791 KAISER AVE IRVINE, CA 92614
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: GENOMICS SCREENING FOR ANTIANGIOGENESIS DRUGS
Agency: HHS
Contract: 1R43CA097900-01
Award Amount: $99,701.00
 

Abstract:

DESCRIPTION (provided by applicant): We will develop a system for testing new anti-angiogenesis compounds using vascular endothelial cells (VEC) derived from fresh human tumors. In Phase I we will validate the proposed protocol by correlating the DNA microarray data with current information on SU5416 and SU6668 anti-angiogenesis activity, thereby laying a foundation for Phase II studies on microarray analysis of tumor-derived VEC treated with various anti-angiogenesis drugs. SU5416 and SU6668 block the signal transduction activity of critical proangiogenic growth factor receptors and selectively target the formation of tumor vasculature. The principal hypothesis to be tested in Phase I is that treatment of tumor VEC with SU5416 or SU6668 will result in drug-specific changes in the expression of genes involved in angiogenesis pathways. The main strategic advantage of Oncotech in the field of anti-angiogenesis drug discovery is the availability and continuous flow of fresh tumor pecimens. PROPOSED COMMERCIAL APPLICATION: The proposed testing will be performed at Oncotech for biotechnology companies on a fee-for-service basis. With over 15,000 fresh tumor specimens projected for Oncotech in 2005, the potential revenues from the proposed business model may reach $ 18 mln per year. The total global market size for anti-angiogenesis drugs in cancer could reach $ 3 billion by 2005.

Principal Investigator:

John P. Fruehauf

Business Contact:

T. Schneggenburger
9494749262
TSCHNEGGENBURGER@ONCOTECH.COM
Small Business Information at Submission:

ONCOTECH, INC.
ONCOTECH, INC. 1791 KAISER AVE IRVINE, CA 92614

EIN/Tax ID: 330141150
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No